| Project/Area Number |
23791209
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Pediatrics
|
|---|
| Research Institution | Foundation for Biomedical Research and Innovation |
|---|
Principal Investigator |
KUSAKAWA Shinji 公益財団法人先端医療振興財団, 細胞療法研究開発センター, 研究員 (80462802)
|
|---|
| Project Period (FY) |
2011-04-28 – 2015-03-31
|
| Project Status |
Completed (Fiscal Year 2014)
|
| Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2014: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2013: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2012: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2011: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
|
|---|
| Keywords | iPS細胞 / 心筋細胞 / 残存未分化細胞 / 未分化多能性幹細胞 / 分化誘導 / 心筋分化 / 多能性幹細胞 / 未分化細胞 / 催奇形性 / 再生医療 / ヒトiPS細胞 / ヒト間葉系幹細胞 / 心筋分化誘導因子 |
|---|
| Outline of Final Research Achievements |
The efficient technology for cardiomyocyte differentiation method from human induced pluripotent stem (iPS) cells was developed in the present research. Firstly, transgenic iPS cells, which showed the specific expression of fluorescent protein in their undifferentiated state, were generated. This enables to conduct qualitative and/or quantitative analysis of the extent of differentiation of human pluripotent stem cells. Secondly, an existing drug was identified to kill undifferentiated iPS cells, but not to avoid the viability of differentiated cells. By using this drug, the establishment of purification method of cardiomyocyte from human iPS cell-derived differentiated cell clusters is prospective. Combined application of these results might provide an approach to identify novel factors, which promote cardiomyocyte differentiation.
|
